Study Vouches Triamazon s Efficacy In Selective Destruction Of Cancer Cells
Research shows significant selectivity against no less than 12 cancers including colon lung breast pancreatic lymphoma liver the list goes on ..., says a report.
Independent research was conducted by the department of chemistry and pharmacognosy, school of pharmacy and pharmacal sciences at Purdue University in West Lafayette Indiana USA.
Explaining the workings of the substance, a spokesman and pharmacologist in Purdue's research says: "Cancer cells that survive chemotherapy can develop resistance to the agent originally used as well as to other, even unrelated, drugs. This phenomenon is called multi-drug resistance (MDR). "One of the main ways that cancer cells develop resistance to chemotherapy drugs is by creating an intercellular pump which is capable of pushing anticancer agents out of the cell before they can kill it. On average, only about two per cent of the cancer cells in any given person might develop this pump-but they are the two per cent that can eventually grow and expand to create multi-drug-resistant tumours. Some of the latest research on acetogenins reported that they were capable of shutting down these intercellular pumps, thereby killing multi-drug-resistant tumours." Purdue researchers also reported that the acetogenins preferentially killed multi-drug-resistant cancer cells by blocking the transfer of ATP-the chief source of cellular energy-into them. A tumour cell needs energy to grow and reproduce, and a great deal more to run its pump and expel attacking agents. By inhibiting energy to the cell, it can no longer run its pump.
When acetogenins block ATP to the tumour cell over time, the cell no longer has enough energy to operate sustaining processes-and it dies. Normal cells seldom develop such a pump; therefore, they don't require large amounts of energy to run a pump and, generally, are not adversely affected by ATP inhibitors. Purdue researchers reported that 14 different acetogenins tested thus far demonstrate potent ATP-blocking properties. They also reported that 13 of these 14 acetogenins tested were more potent against MDR breast cancer cells than all three of the standard drugs (adriamycin, vincristine, and vinblastine) they used as controls.
The results on this research have been listed in Pubmed The National Library of Medicine and The National Institutes of Health.
A spokesman for triamazon stated, "This has been a long time in coming, and shows that this all natural drug Triamazon is far superior as there are no side effects no drug interactions is non toxic and safe we are delighted this breakthrough in natural alternative medicine has been born and because Triamazon is of natural non-patentable substances this means its very affordable and will be within the reach of anyone suffering from cancer, the study concludes.
Submitted by: Andrew Harris
Andrew Harris. info@triamazon.com
Source: http://ezinearticles.com/
Added: May 21, 2008
Cancer Researchers Should Widen Genetic Focus, Studies Suggest - Bloomberg
U.S. Hospitals flunk colon cancer exam - Los Angeles Times
Court 'end of road' for cancer man - The Press Association
BBC News Court 'end of road' for cancer man The Press Association - A High Court bid to get a West Sussex man a cancer drug is an "end of the road" attempt, his lawyer has said. Colin Ross, 55, of Horsham, has cancer of the ... Cancer drug battle goes to court High Court Battle For Cancer Drugs Postcode lottery fight for cancer sufferer -